FCGR2A and neoplasm: It was demonstrated by Mangeat et al. that in tumor‐bearing mice, the insertion of the LALAPG triple mutation in [89Zr]Zr‐DFO‐antibodies against several targets reduced FcγR binding and liver accumulation.[53] They noticed that compared to wild‐type antibodies, the Fc‐engineered antibodies showed greater tumor‐to‐liver ratios and decreased liver absorption.